0001553878-17-000009.txt : 20170203
0001553878-17-000009.hdr.sgml : 20170203
20170203163258
ACCESSION NUMBER: 0001553878-17-000009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170201
FILED AS OF DATE: 20170203
DATE AS OF CHANGE: 20170203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SHARP PHILIP A
CENTRAL INDEX KEY: 0001226295
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 17572573
MAIL ADDRESS:
STREET 1: BIOGEN INC LEGAL DEPARTMENT
STREET 2: 14 CAMBRIDGE CENTER
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2017-02-01
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001226295
SHARP PHILIP A
300 THIRD STREET
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2017-02-01
4
M
0
25000
31.29
A
165795
D
Common Stock
2017-02-01
4
S
0
20171
39.72
D
145624
D
Common Stock
2017-02-01
4
S
0
4829
40.16
D
140795
D
Common Stock
126104
I
by Trust
Stock Option (right to buy)
31.29
2017-02-01
4
M
0
25000
0.0
D
2008-12-12
2017-12-13
Common Stock
25000
0
D
The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.
Sale prices ranged from $39.09 to $40.08
Sale prices ranged from $40.10 to $40.24
The 126,104 shares reported as indirectly owned by trust include: (i) 94,838 shares in the Phillip A. Sharp 2009 Grantor Annuity Trust No. 3, and (ii) 31,266 shares in the
Phillip A. Sharp 2008 Grantor Annuity Trust No. 2 (which include shares distributed from the 2010 Trust).
By: /s/ Michael P. Mason, Attorney-in-Fact For: Phillip A. Sharp
2017-02-03